With improved understanding of the pathophysiology and natural history of inflammatory bowel disease (IBD), new treatment goals are evolving and therapeutic strategies continue to be refined. This supplement summarizes the discussions regarding the natural history of IBD, strategies for optimizing both conventional and biologic agents, and the relevance of various therapeutic end points that were featured in a recent symposium and explores issues of high relevance to clinicians who treat patients with IBD.
Target Audience
This activity has been designed to meet the educational needs of gastroenterologists and other health care professionals involved in the care of patients with IBD.
Learning Objectives
After completing this activity, participants should be able to: l Compare clinical and endoscopic end points for treatment of ulcerative colitis and Crohn's disease l Recognize predictors of disease course in IBD l Develop treatment plans that utilize clinical predictors to optimize therapy for individual patients l Design treatment plans that incorporate the appropriate selection and timing of conventional agents or biologic agents for ulcerative colitis or Crohn's disease
Accreditation
The University of Chicago Pritzker School of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.